ARS Pharmaceuticals (SPRY) Non-Current Assets (2020 - 2026)

ARS Pharmaceuticals has reported Non-Current Assets for 7 years, with the latest figure at $42.3 million in Q1 2026.

• Quarterly Non-Current Assets rose 80.47% year-over-year to $42.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151.1 million (up 200.0% YoY) and the FY2025 annual result came in at $42.8 million, up 153.62% from the prior year.
• Non-Current Assets eased to $42.3 million in Q1 2026 per SPRY's latest filing, from $42.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $51.1 million in Q1 2022 and troughed at $265000.0 in Q3 2022.
• A 5-year average of $17.8 million and a median of $8.8 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 99.44% in 2022, then soared 2508.79% in 2025.
• Over 5 years, Non-Current Assets stood at $3.7 million in 2022, then sank by 60.86% to $1.5 million in 2023, then surged by 1053.08% to $16.9 million in 2024, then surged by 153.62% to $42.8 million in 2025, then dropped by 0.98% to $42.3 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $42.3 million, $42.8 million, and $33.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.